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Historically, in ancient civilization, man had already imagined changes in the morphology, 
structure and function of the human body. Egyptian and Greco-Roman mythology provided 
examples of the metamorphoses sung by Homer and Ovid, symbolic incarnations of the 
“comedie humaine” with its strength, weakness, vices and virtues. The liver has been the 
noble organ, the organ of life from time immemorial-liver in English, Leber in German, 
derived from the verb to live. An Indian legend from the 12th century B.C recounts the 
power of Shiva, who xenotransplanted an elephant head onto a child induce the Indian god 
Gaesha.[1] In ancient China, Yue-Jen (407-310 B.B.) induced anesthesia lasting 3 days by “the 
absorption of extremely strong wine, opened up the chest of two soldiers and after 
examining them, exchanged their hearts and transplanted them”. The first reference to the 
concept of organ transplantation and replacement for therapeutic purposes appears to be 
Hua-To (136 to 208 A.D.) who replaced diseased organs with healthy ones in patients under 
anesthesia induced with a mixture of Indian hemp.  
Although attempts at transplantation date back to ancient times, the impetus for modern 
transplantation was World War II and Battle of Britain. Royal Air Force pilots often were 
severely burned when their planes crashed. The mortality rate associated with burns 
corresponds to the size of the area of the skin that has been injured and the survival rate can 
be improved if the burned skin is replaced. For this reason, British doctors, attempted skin 
transplantation from other human donors as a mode of therapy. However, these attempts 
were uniformly unsuccessful. The transplanted skin became necrotic and fell off over 
several days.[2] This problem led investigators in 1940s to study skin transplantation in 
animal models. It remained for Sir Peter Medawar in 1944 to establish that the failure of a 
skin graft to “take” was the result of a process later termed immunological rejection.[3] Later 
studies by Gowens in 1948 revealed that lymphocytes play a major role in transplant 
rejection.[4] In 1951, it was shown that cortisone therapy significantly prolonged survival of 
skin allograft.[5] In 1959, Schwartz and Dameshek reported drug-induced immune-tolerance 
using 6-mercaptopurine.[6] Later in 1961, Calne and Murray showed that azathioprine 
therapy suppressed the rejection reaction and prolonged allograft survival.[7]  
Once clinicians were confident that adequate immunosuppression was available, solid 
organ transplantation for end stage organ disease entered its early investigative phase. This 
was not possible without the application of the principles of vascular anastomosis pioneered 
by Alexis Carrel in 1902, for which he was awarded the Nobel Prize for Medicine in 1912.[8] 
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Further refinements in surgical techniques and suture materials have enabled Murray and 
his colleagues to perform the first successful kidney transplant in 1955.[9] This was a living 
donor transplant performed between identical twins. However, later attempts to perform 
renal transplantation when the donor and recipient were not genetically identical failed 
because no effective immunosuppressive therapy was available. From the early 1960s, a 
combination of azathioprine and corticosteroids was used with success to prevent graft 
rejection after kidney transplantation. In 1963, Woodraff described the immunosuppressive 
effect of antilymphocytic serum which destroyed the recipient active lymphocytes.[10] The 
success of kidney transplantation paved the way to think and perform liver transplantation 
for end-stage liver disease. 
In 1955, Welch reported on his efforts to transplant an auxiliary liver into the right 
paravertebral gutter of non-immunosuppressed mongrel dogs.[11] In 1958, Francis Moore 
described the standard technique of canine liver orthotopic liver transplantation.[12] In 
1963, Starzl attempted the first human orthotopic liver transplantation in a 3-years-old boy 
who suffered from biliary atresia, however, the patient died before the operation was 
completed.[13] Following this first unsuccessful attempt, the procedure evolved slowly and 
although his series remained largely unsuccessful, many of the technical principles that still 
guide liver transplantation were established. In 1967, Starzl and colleagues at the University 
of Colorado reported the first successful clinical liver transplantation.[14]  
Between 1966 and 1973, Starzl and colleagues performed three chimpanzee-to-human 
xenotransplantation of liver as well.[15] There have been 12 cases of clinical 
xenotransplantation including four cases of champazee-to-human, seven cases of baboon-to-
human and one case of pig-to-human.[16]  
In 1978, Roy Calne opened liver transplantation unit in Cambridge, UK, and performed the 
first liver transplantation in Europe and the second largest transplantation series in the 
world.[17] Until 1977, Starzl and Calne contributed the majority of performed liver 
transplantation worldwide.[18]  
The first hetero-topic liver transplants in man were reported by Apsolon in 1965; however, 
the first long-term survivor with this technique was reported by Fortner in 1973.[19]  
In 1984, Shaw et al introduced the venovenous bypass system at Pittsburg University, 
leading to better hemodynamic stability during the standard liver transplantation.[20]  
At the same time, Broelsch et al.[21] in the USA and Bismuth et al.[22] in France performed 
independently the first reduced-size liver transplantation. Thereafter, Pichlmayr et al.[23] 
reported the first split liver transplantation 1988. Meanwhile, Tzakis et al. introduced the 
piggyback technique with preservation of the recipient’s vena cava.[24] With the increasing 
number of the patients on the waiting list, transplantation of partial liver grafts from living 
donors evoluted to increase the donor pool. For this purpose, Broelsch et al. established the 
technique of segmental living donor liver transplantation (LDLT), and Strong et al. 
performed the first successful LDLT in 1989, implanting a left lateral segment into a 
pediatric patient.[25] In 1990, Broelsch et al. reported the first series of LDLT in the USA.[21] 
In 1991, the first domino liver transplantation using liver from donors affected by familial 
amyloidotic polyneuropathy type I was introduced by Holmgren at al.[26] In 1992, Belghiti 
and coworkers introduced a modified piggyback technique with a cavo-caval side-to-side 
www.intechopen.com
 
History and Evolution of Liver Transplantation 
 
5 
anastomosis.[27] One year later, Hashikura and colleagues transplanted a left hepatic lobe 
into an adult recipient in 1993,[28] and Yamaoka et al. implanted a right lobe into a pediatric 
recipient.[29] In 1996, Lo et al. performed the first successful liver transplantation using an 
extended right lobe from a living donor for an adult recipient.[30] In 1998, Tzakis et al. 
introduced liver transplantation with cavo-portal hemitransposition in the presence of 
diffuse portal vein thrombosis.[31] In 2002, Cherqui et al. reported first donor hepatectomy 
by a full laparoscopic procedure in which a left lateral lobectomy was successfully 
performed for liver transplantation in a child.[32] 
2. Evolution of immunosuppression 
Rejection of the transplant remained a major problem until cyclosporine-A was discovered 
by Jean Borel.[33] The 1-year survival rate following liver transplantation was 30% to 50% 
prior to the discovery of cyclosporine-A,[34,35] however, after the introduction of 
cyclosporine-A, the 1-year and 3-year survival rates were 74% and 67% in the first 1000 
recipients treated with cyclosporine-A at the University of Pittsburgh in the early 1980s.[36] 
After these good results, growth of liver transplantation was facilitated by the conclusion of 
the National Institute of Health Consensus Development Conference in 1983 that liver 
transplantation is not an experimental procedure but an effective therapy that deserves 
broader application.[34] Shortly thereafter, the first monoclonal antibody OKT3 was 
discovered by Cosimi in 1981 and proved effective in treating acute transplant rejection and 
was sometimes used along with cyclosporine-A based regimen as immunoprophylaxis 
especially in North American Centers or to treat steroid resistant graft rejection.[37] Since 
then, many new immunosuppressive agents were introduced. In 1990, Mycophenolate 
mofetil (MMF, CellCept) was introduced by University of Wisconsin and proved, in 
combination with cyclosporine-A, to further reduce the incidence of graft rejection episodes 
better than azathioprine with less toxic effects.[38] In the same year, Rapamycin (Sirolimus) 
was introduced.[39] It is like cyclosporine-A but it has a different mechanism of action. It 
inhibits lymphocyte proliferation through prevention of ligation of IL-2 to the IL-2 
receptors.[40] In 1994, Ochiai in Japan introduced tacrolimus (FK506, Prograf) and proved to 
reduce the incidence of transplant rejection more than cyclosporine A. It is like cyclosporine-
A but hundred times more potent and is indicated in severe acute rejection resistant to 
standard immunosuppressive protocols and in chronic rejection.[41] 
Greater understanding of the underlying liver disease, improved surgical and anaesthetic 
techniques, reliable immunosuppression and dependable postoperative care over the last 
few years have contributed towards improved results of liver transplantation. This success 
has resulted in a disproportionate increase in demand of liver transplantation and the 
appearance of a major problem of shortage of available donor organs, leading to a 
prolonged waiting times and high mortality on the waiting list.[42]  
3. The progress in liver transplantation with donor shortage 
The donor shortage together with the development of surgical skills of liver resections based 
on the knowledge of segmental anatomy of the liver described by Couinaud,[43] opened the 
door for innovative methods of transplantation including auxiliary liver transplantation, 
reduced-liver transplantation (RLT), split liver transplantation (SLT) and living donor liver  
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transplantation (LDLT).[44,45] Also, The donor shortage had led to the evolution of 
hepatocyte and stem cells transplantation which will be the future in the liver 
transplantation.  
3.1 Auxiliary liver transplantation 
Auxiliary liver transplantation (ALTx) consists of either implanting a healthy liver graft 
placed heterotopically or orthotopically while leaving all or part of the native liver. This 
concept was originated from an experimental work of Welch in 1955.[46, 47]  
The first auxiliary liver transplantation in human was performed by Absolon in 1964,[48] 
and it was till 1972 when an auxiliary transplantation truly prolonged a human life.[49] 
During the following two decades, ALTx was done solely in a heterotopic manner -
heterotopic auxiliary liver transplantation (HALTx), where a graft (usually partial) is placed 
below the un-resected native liver. The initial clinical results of HALTx were rather 
disappointing with a high rate of technical failure, probably due to inadequate portal 
perfusion of the graft and insufficient drainage of hepatic blood flow in an area of low 
pressure which had led to temporary abandonment of HALTx in the early 70s.[50-52]  
Many efforts have been made ever since to improve post-transplant survival. Most notably, 
based upon the experiences in animal studies,[52-58] the contributions of Terpstra’s group 
have improved the surgical techniques of HALTx with markedly increased post-HALTx 
survival rate.[58-63] Since 1980s’, the concept of ALTx has further been extended by the 
introduction of a new approach –auxiliary partial orthotopic liver transplantation 
(APOLTx), where the left or the right lobe of the native liver is resected and replaced by an 
auxiliary graft.[64-71] The physiological position of the hepatic graft by this approach results 
in an optimal outflow pressure. Accumulating clinical results have shown a reduced 
incidence of post-transplant portal thrombosis.[65, 72, 73] 
For certain types of non-cirrhotic metabolic disorders, such as type 1 Crigler-Najjar 
syndrome, urea cycle enzyme deficiencies, disorders of fatty acid metabolism, familial 
hypercholesterolemia, hemophilia and ornithine transcarbamylase deficiency, an auxiliary 
liver may correct the partial enzymatic deficiency responsible for the disease without the 
need to remove the otherwise normal native liver.[65, 66] A significant minority of patients 
with acute liver failure who fulfill the transplant criteria would have had complete 
morphological and functional recovery of their liver if they had not undergone orthotopic 
liver transplantation.[74] These considerations have led to the concept of auxiliary liver 
transplantation, which doesn’t exclude the potential for spontaneous regeneration of the 
native liver and eventual withdrawal of immunosuppression drugs.[75-78]  
In selected patient aged <40 years without hemodynamic instability, the use of ABO 
compatible, non-steatotic grafts harvested from young donors with normal liver function, 
can restore normal liver function and prevent the occurrence of irreversible brain damage. 
After standard immunosuppression, the recovery of the native liver is assessed by biopsies, 
hepatobiliary scintigraphy and computed tomography. When there is evidence of sufficient 
regeneration of the native liver, immunosuppression can be discontinued progressively. 
Complete regeneration of the native liver can be observed in >50% of patients, who can be 
withdrawn from immunosuppression. Therefore, the advantages of the auxiliary liver 
transplantation seem to balance with the potential inconvenience of this technique in 
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selected patients.[79-81] ALTx also preserves the patient’s native liver, which remains 
accessible for future gene transfer therapy.[82] 
3.2 Reduced-sized liver transplantation (RLT) 
It was first reported in 1984 by Bismuth, and involves ex-vivo resection of an adult cadaveric 
liver in order to create an appropriate sized liver graft for an infant or small child. It was 
introduced as a surgical solution for decreasing the pediatric liver transplant waiting list 
mortality using organs from donors much larger than the recipient, but does not increase 
the total number of livers available for transplantation. This is because the reduced-sized 
portion is not used and discarded.[22]  
Initially, RLT was criticized because it disadvantaged adult patients awaiting liver 
transplantation and was to be associated with inferior results. The allegations regarding 
inferior graft and patient survival were proven wrong,[83-85] and several proponents of this 
technique actually reported a lower incidence of vascular complications since the caliber of 
the hepatic artery was larger than that seen in a pediatric donor.[86] Since this technique 
resulted in discarding the remaining portion of liver, it clearly had a negative impact on 
adult population awaiting liver transplantation, and for that reason, is rarely used today. 
3.3 Split liver transplantation (SLT) 
In 1988, Pichlmayer in Germany and Bismuth in France simultaneously performed split liver 
transplantation (SLT), an ex-vivo splitting of a cadaveric liver allowing transplantation to a 
pediatric recipient and one adult.[23, 87] Unlike RLT, SLT resulted in an increased number 
of organs in donor pool with each cadaveric liver giving rise to two functioning allografts. 
The initial results of SLT, reported by Broelsch,[21] had a high rate of graft failure with a 
survival rate of only 67% in children and 20% in adults receiving a split liver transplants. In 
addition, 35% of patients required retransplantation and more than a quarter had biliary 
complications.[22] More recently, in-situ SLT has provided patient and graft survival similar 
to that seen in whole cadaveric transplantation.[88-90] The practical feasibility of split-liver 
transplantation as well as the increased safety of conventional liver surgery suddenly 
opened up the idea of removing part of the liver from a living donor. 
3.4 Living donor liver transplantation (LDLT) 
This has been made possible by recent advances in hepatic surgery; first, improved 
understanding of the anatomy and the techniques of hepatic resections,[91] second, growing 
evidence that the operative risk of partial hepatectomy in a non-cirrhotic liver is extremely 
low,[92, 93] third, widespread success with RLT,[25, 83-85, 94] and fourth, the successful 
application of SLT.[95] 
3.4.1 LDLT in pediatrics 
LDLT was first introduced in pediatric population. In 1988, Raia in Brazil reported the first 
LDLT, establishing the technical feasibility of this procedure, yet both pediatric recipients 
died of complications.[96] Strong and colleagues subsequently reported the first successful 
pediatric LDLT using a left lobe graft from the child’s mother.[25] Broelsch reported the first  
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successful series of LDLT with an overall graft survival of 75% and patient survival of 
85%.[97] Furthermore, he was the first to report a prospective ethical analysis of this radical 
surgical innovation prior to performing their first LDLT.[98]  
LDLT in children involves the removal of an adult donor left lateral segment (segment 2 and 
3). Monosegment transplantation (segment 3) was introduced in Japan to solve the problem 
of “Large for size” grafts in small children.[99] The donor operation has been associated 
with a low and acceptable risk for complications. The donors being related to the recipients 
(parents), the risk for the donor is balanced by the great benefit to be received by the 
transplant recipient, as well as the donor’s psychological benefit. 
LDLT was initially restricted to children with chronic disease, in relatively stable condition, 
in order to avoid a major psychological pressure on the potential donor.[98] With larger 
experience, it was extended to emergency cases such as fulminant hepatic failure. Auxiliary 
transplantation, initially developed in this indication,[78] and in metabolic disorders,[100] 
could also be performed with a living donor liver.[101-104] 
The continued shortage of cadaver livers in the face of growing list of recipients plus the 
advantages of LDLT have led to the introduction of LDLT in adults. 
3.4.2 Adult-to-adult LDLT 
The expansion of LDLT to the adult population began in the countries where the availability 
of deceased donors was scarce, and in some cases, totally unavailable.[105-107] The law for 
deceased organ retrieval was instituted in Japan in 1998, however, the lack of societal 
acceptance of organ retrieval from brain dead donors resulted in live donation being the 
main source of grafts for patients awaiting transplantation in Japan and other countries in 
Asia.[108] 
On November 2, 1993, the Shinshu group performed the first successful adult-to-adult 
LDLT.[28] By June 2002, there were 433 adult LDLT cases recorded in European Liver 
Transplantation Regestery,[109] with 3 years graft and patient survival rate of 65% and 68% 
respectively. According to the United Network for Organ Sharing (UNOS), 731 adult LDLT 
cases have been performed in the United States by October 2001. The 3 years graft survival 
was 47% between 1998 and 1999 (n=156) but it improved significantly to 61% between July 
1999 and June 2001 (n=285).[110] According to the Japanese Liver Transplantation Society, 
1063 adult LDLT procedures were performed in Japan by the end of 2002. The 5 years 
survival rates were 83% in children and 69% in adults.[111] The lesser outcome in adults 
compared to that in children indicates that problems remain in adult LDLT. 
In LDLT, donor safety must be assured. This may be achieved by optimizing graft size to 
ensure safety of both donor and recipient, technical expertise in liver procurement from 
the donor as well as ethical problems of using non-related live donors. As regarding the 
optimum size of the graft, it was found that, a graft volume of >40% of the recipient 
standard liver volume is necessary,[112] while for the living donor the remnant liver mass 
must be more than 30% of the whole liver.[113] The term “standard liver volume” has 
become a key concept in LDLT and it has been estimated using the following 
formula:[114] 
Standard liver volume (SV) in ml = 706.2 x (body surface area [m2]) + 2.4. 
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In order to obtain the optimum graft size in adult-to-adult living donor transplantation, 
many graft types has been introduced. The strategy of selection of left or right liver graft is 
influenced by the patient’s preoperative condition as patient with advanced liver disease 
require a larger liver mass.[115] The model for end-stage liver disease (MELD) score could 
become a satisfactory criterion for differentiating between high and low-risk patients and 
therefore determine the type of graft to use.[116] In the initial adult LDLT procedures only a 
left liver graft was used. In 1998, the Shinshu group reported satisfactory results using a left 
liver graft in 13 patients.[107] To cover wide range of recipient body weight, the right lobe 
graft was introduced in 1998 in Kyoto university.[117] In the same year, the University of 
Colorado group also introduced the right liver graft in adult LDLT,[118] the group performed 
80 adult LDLT. In the first 10 cases, the right lobe graft was procured without the middle 
hepatic vein (MHV), 3 grafts were lost. As a result, the group included the MHV in the right 
lobe graft in the subsequent 70 cases. No graft loss was experienced.[119] The reason may be 
due to the prevention of congestion of the anterior segment of the right lobe which is 
drained by the MHV. However, the right lobe graft including the MHV was first introduced 
by the Hong Kong group in 1996.[106] In this situation, the volume of the remnant liver 
should be at least greater than 30% and the anatomy of vein 4 must be precisely evaluated 
before this procedure is accepted. However, the outcome of initial 8 donors and recipients 
were not without complications, one recipient died and the recipients as well as the donors 
experienced high morbidity.[106] The next 92 patients subsequently received extended right 
liver grafts (right lobe graft including the MHV) with the following innovations: elimination 
of venovenous bypass from the routine protocol, preservation of segment 4 venous drainage 
for donors, venoplasty of MHV and right hepatic vein (RHV) into a single orifice for better 
venous return and easy vein reconstruction in recipients and preservation of the blood 
supply to the right hepatic ducts. Over time the mortality rate of recipient decrease from 
16% in the initial 50 cases to 0% in more recent patients.[120] 
Lee, aggressively reconstructed the MHV tributaries in right liver grafts without the MHV 
trunk and named this type of graft a modified right lobe graft.[121] Ghobrial, also 
recommended reconstruction of the MHV tributary veins when the RHV in the graft was 
<1.5 cm in diameter.[90] All MHV tributaries with a size >5 mm should be preserved during 
donor hepatectomy and reconstructed with autogenous interposition vein grafts.[122] 
Right hepatectomy imposes an increased surgical risk on the donor due to the reduced 
residual liver volume. A recent report indicated that in 25% of potential donors, the right 
liver had an estimated volume of >70% of the whole.[123] Since safe donation was possible 
only when estimated residual liver volume was >30%, right hepatectomy is not possible for 
some potential donors. The University of Tokyo group was the first to design the right 
lateral sector graft consisting of segment 6 and 7 in those donors with right livers over 70% 
of liver volume and the estimated volume of the right lateral segments is greater than that of 
the left liver and at the same time >40% of the recipient’s standard liver volume.[124] 
Between January 2000 and April 2001, 6 of 32 adult-to-adult LDLT with a right lateral sector 
graft were performed. The postoperative course was uneventful in all donors and all 
recipients survived the operation.[125]  
Lee et al, were the first to devise dual grafts from 2 living donors.[126] Most commonly, 
both donors donate the left liver or left lateral segment. The first left liver graft is 
orthotopically implanted in the original left position, the second left liver graft is rotated 180 
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degrees and positioned heterotopically in the right upper quadrant fossa. Because the bile 
duct is now located behind the portal vein and hepatic artery, bile duct reconstruction is 
necessary before reconstruction of vessels. An interposition vein graft might be necessary 
for the reconstruction of the hepatic or portal vein. By the end of 2003, this technique was 
used in 93 patients with satisfactory results. However the procedure has limited appeal due 
to the high requirements of economic and medical resources including 3 operating rooms 
and 3 surgical teams working simultaneously.[127]  
4. Hepatocyte and stem cells transplantation 
Additional approaches, as therapeutic alternative in attempt to reduce the significant 
mortality in the waiting list for liver transplantation is hepatocyte transplantation. A 
number of experiments have shown the feasibility of total liver parenchymal cell 
replacement by transplanted hepatocytes.[128-132] Hepatocyte transplantation might be 
able to bridge a period needed for regeneration of the acute liver failure patient’s own liver 
or stretch the waiting time for a suitable liver donation. Although the first animal 
experiments with this technique began in 1967 [133], it was first applied in humans only in 
1992.[134] Isolated Hepatocyte transplantation has long been recognized as a potential 
treatment for life-threatening liver disease. The basis for proceeding with clinical trials has 
been provided by extensive laboratory work in animal models.[135-140] The most important 
advantage of this treatment compared to liver transplantation, is its simplicity, since no 
surgery is required for cell implantation. The cell transplantation has been used for, 
temporary metabolic support of patients in end-stage liver failure awaiting whole-organ 
transplantation, as method to support liver function and facilitate the regeneration of the 
native liver in cases of fulminant hepatic failure, and in a manner similar to gene therapy as 
a form of “cellular therapy” for patients with genetic defects in vital liver functions. The 
patients can be treated by the infusion of 107-1010 allogenic hepatocytes, obtained from adult 
cadaveric livers, into the splenic artery or portal vein.[141] The main obstacle to wider usage 
of hepatocyte transplantation is the rapid elimination of the transplanted hepatocytes by 
recipient macrophages.[142] 
Alternatives to the transplantation of allogenic human hepatocytes include the transplantation 
of hepatocytes derived from fetal, adult, or embryonic stem cells, engineered immortalized 
cells, or hepatocytes derived from other animal species.[143] Stem cells are one of the best 
approaches to obtaining cell stores. This approach can be used for clinical treatment by 
selecting small cell population that could effectively repopulate the host liver.[144] 
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